Healthcare / Diagnostics & ResearchBSE
$56.00
+0.90 (+1.63%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 18%
FCF escenarios
weak_data · normalized FCF $-31.0M · quality 42.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
31/100
D
Piotroski
6/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
12/100
SEC 0%
Sin guardar todavía.
Market Cap
$846M
P/E
9.4x
↓EV/EBITDA
5.6x
↓ROE
43.3%
↑Gross Margin
72.3%
↑Debt/Equity
1.07
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2023–2025 · 2 años de histórico normalizado
Revenue CAGR
+17.7%
FCF CAGR
—
FCF margin
0.7%
FCF / Net income
0.06x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $779.5M · net income $89.7M · FCF $5.7M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 |
|---|---|---|---|---|
| Income Statement | ||||
| Revenue | $779.5M | $779.5M | $671.3M | $562.8M |
| Net Income | $89.7M | $89.7M | $57.9M | $-57.3M |
| EBITDA | $187.7M | $187.7M | $125.7M | $-6.9M |
| EPS | — | — | 3.84 | -3.80 |
| Gross Margin | 72.3% | 72.3% | 70.1% | 63.0% |
| Operating Margin | 17.7% | 17.7% | 10.8% | -8.4% |
| Net Margin | 11.5% | 11.5% | 8.6% | -10.2% |
| Balance Sheet | ||||
| Debt/Equity | 1.07 | 1.07 | 1.74 | 2.57 |
| Current Ratio | 1.05 | 1.05 | — | — |
| Cash Flow | ||||
| Free Cash Flow | $5.7M | $5.7M | $-31.0M | $-34.5M |
| Returns | ||||
| ROE | 43.3% | 43.3% | 49.3% | -96.1% |
| Valuation | ||||
| P/E | 9.43 | 9.43 | — | — |
| EV/EBITDA | 5.64 | 5.64 | — | — |
| P/B | 4.08 | 4.08 | — | — |
| Growth & Yield | ||||
| Revenue Growth | 16.1% | 16.1% | 19.3% | — |
| EPS Growth | — | — | 201.1% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-41.0%
Start / end P/E
n/dx → n/dx
EPS bridge
3.84 → n/d
Residual
-41.0%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.